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Objective: Genetic background of cryptogenic ischemic stroke (IS) and transient ischemic
attack (TIA) remains uncertain. Alpha-2-antiplasmin (a2AP) Arg407Lys polymorphism has
been shown to be less common in patients with abdominal aortic aneurysm (AAA) compared
with healthy controls. We investigated associations of a2AP Arg407Lys polymorphism with
cryptogenic IS and TIA.
Methods: We studied 165 consecutive Caucasian patients who experienced cryptogenic IS
(n = 123) or TIA (n = 42). Neurological outcomes were assessed using the modiﬁed Rankin
Scale (mRS) in the acute phase of cerebral ischemia and 8 (6–12) months after the index
episode. Patients were genotyped for a2AP Arg407Lys polymorphism (rs1057335) using real
time PCR technique.
Results: The allele frequency of Arg407Lys polymorphism was: 0.82/0.18. The 407Lys allele
was more frequent in TIA patients compared to the IS group (0.29 vs. 0.14, p = 0.003). In the
whole group, as well as in IS and TIA patients analyzed separately, possession of the 407Lys
allele was associated with excellent outcome (mRS 0–1) during follow-up ( p < 0.05) but not in
the acute phase of ischemic events both in thrombolyzed and nonthrombolyzed IS patients.
The multivariate logistic regression model showed that the excellent outcome (mRS 0–1)
assessed after 8 (6–12) months since the index cerebral ischemia was predicted by the
occurrence of Lys407 allele (OR 6.18, 95% CI, 2.01–18.98, p = 0.001).
Conclusion: The presence of 407Lys allele is associated with better prognosis in cryptogenic
cerebrovascular events. Our ﬁndings suggest that the a2AP Arg407Lys polymorphism could
be involved in the pathogenesis of cerebral ischemia and its outcomes.
© 2017 Published by Elsevier Sp. z o.o. on behalf of Polish Neurological Society.
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Genetic background of transient ischemic attack (TIA) and
ischemic stroke (IS) remains unclear. Substantial genetic and
pathophysiological heterogeneity of stroke has been indicated
by genome wide association study (GWAS) [1,2]. Little is known
about the association of cerebrovascular events with genetic
variants of proteins involved in ﬁbrinolysis.
Alpha-2-antiplasmin (a2AP), the main physiological inhib-
itor of plasmin, has been shown to reduce the efﬁcacy and
safety of tissue plasminogen activator (tPA) therapy for IS in
mouse models [3,4]. a2AP inactivation during tPA treatment
improved thrombus dissolution and reduced brain infarction,
swelling and hemorrhage. In contrast to the protective effects
of a2AP deﬁciency or inactivation in cerebral ischemia, higher
a2AP levels correlated with greater ischemic brain injury and
reduced middle cerebral artery thrombus dissolution [4].
Until now, 5 mutations causing congenital a2AP deﬁciency
and three polymorphisms, Arg6Trp, Ala26Val and Arg407Lys
of unknown clinical signiﬁcance have been identiﬁed [5,6]. The
a2AP Arg407/Lys polymorphism has been found ﬁrst in three
family members with bleeding tendency [6]. In patients with
abdominal aortic aneurysm (AAA), Arg407Lys and Arg6Trp
polymorphisms were associated with total plasma a2AP levels
that were higher in AAA patients as compared to controls [7].
The AAA occurred less frequently in the 407Lys allele carriers
[8]. The a2AP Arg407Lys polymorphism has been found to have
no association with myocardial infarction (MI) risk [9].
We put forward a hypothesis that IS occurs less frequently
in the a2AP 407Lys allele carriers. We investigated relation-
ships of the a2AP Arg407Lys polymorphism and ischemic
cerebrovascular events of unknown origin as well as their
neurological outcomes.
2. Methods
A total of 165 consecutive adult white patients with a history of
cryptogenic IS or TIA aged 70 years or less were referred to the
Center for Coagulation Disorders in Cracow, Poland between
May 2006 and December 2014 in order to exclude thrombo-
philia as a potential cause of cerebrovascular events. Exclusion
criteria were antiphospholipid syndrome (APS), known malig-
nancy, well-established causes of cerebrovascular events (e.g.
documented atrial ﬁbrillation), current anticoagulation, end-
stage renal disease or liver cirrhosis. The diagnosis of IS was
based on clinical symptoms according to the World Health
Organization (WHO) deﬁnition [10] and brain imaging, usually
non-contrast computed tomography (CT). TIA was deﬁned as a
brief episode of neurological dysfunction caused by focal brain
or retinal ischemia, with clinical symptoms typically lasting
less than one hour and without evidence of acute infarction.
Patients were recruited at least 3 months after IS or TIA and the
neurological status was assessed using the modiﬁed Rankin
Scale (mRS) without knowledge of the genetic data [11]. If in
the meantime the patients with TIA suffered from IS, they
were included in the TIA group. Only patients with cerebral
ischemia of obscure or unknown origin were eligible for the
study. To exclude occult paroxysmal atrial ﬁbrillation, patentforamen ovale, aortic arch atherosclerosis, valvular disorders,
atrial ﬁbrillation, and carotid artery atherosclerosis, transtho-
racic and tranesophageal echocardiography, ultrasound scan-
ning of the carotid arteries and 24-hour Holter monitoring
(repeated within the ﬁrst month) were performed.
The University Ethical Committee approved the study, and
patients provided written informed consent in accordance
with Declaration of Helsinki.
The clinical data in the acute phase of cerebrovascular
events, including the therapy used and neurological deﬁcits,
were collected based on medical records.
Thrombophilias, including elevated factor VIII (FVIII),
antithrombin (AT) deﬁciency, protein C (PC) deﬁciency, protein
S (PS) deﬁciency, factor V G1691A (FV Leiden) and factor II
prothrombin G20210A (FII) were assessed as described [12].
Genomic DNA was extracted from whole blood or a buffy
coat following the original protocol using the GenEluteTM
Blood Genomic DNA Kit (Sigma–Aldrich Co., St. Louis, MO,
USA) and stored at 80 8C until analysis. The a2AP polymor-
phism Arg407Lys (rs1057335) was determined using TaqMan
SNP Genotyping Assay on an ABI PRISM 7900HT Fast Real-Time
PCR System (Life Technologies Co., Carlsbad, CA, USA).
2.1. Control group
The distribution of the Arg407Lys polymorphisms genotypes
in 53 healthy controls of the same ethnical background was:
Arg/Arg: 37 (70%) and Arg/Lys: 16 (30%), which agrees with a
previous report [8].
2.2. Statistical analysis
The distribution of the continuous variables was analyzed by
the Shapiro–Wilk test. The variables normally distributed were
compared with the Student's t test (with correction to unequal
variances if appropriate) and presented as mean  standard
deviation. Variables with non-normal distribution were ana-
lyzed by the Mann–Whitney U test and presented as median
[interquartile range]. Categorical variables were presented as
counts (percentages) and analyzed by the Pearson's x2 or
Fisher's exact tests if appropriate. A p-value of <0.05 was
considered statistically signiﬁcant. For multiple comparisons
omnibus Fisher's exact tests with Ŝidâc correction was used.
Simple logistic regression models were used to identify
signiﬁcant determinants of excellent outcome (mRS 0–1).
Multiple logistic regression model was constructed stepwise
backwards among those variables which p-value was smaller
than 0.2 in a simple model.
3. Results
We studied 123 (75%) patients following IS, including 96 (78%)
thrombolyzed individuals, and 42 (25%) after TIA (Table 1).
Fifty-eight (35%) patients had at least one type of thrombo-
philia with the highest prevalence of FVIII >150% (n = 23, 14%)
and FV Leiden (n = 15, 9%). Most of the patients (n = 144, 87%)
were taking low-dose aspirin following cerebrovascular event
(Table 1).
Table 1 – Patient characteristics.
Variables All patients
(n = 165)
IS patients
(n = 123)
TIA patients
(n = 42)
p-value Arg407
patients
(n = 111)
407Lys
patients
(n = 54)
p-value Thrombolyzed
patients
(n = 97)
Non-thrombolyzed
patients (n = 68)
p-value
Age, years 45.6  11.7 45.9  11.4 44.8  11.4 0.87 45.0  11.0 47.9  12.1 0.1 46.2  10.4 45.3  12.9 0.63
Male, n (%) 57 (35) 43 (35) 14 (33) 0.85 40 (36) 17 (31) 0.56 35 (36) 22 (32) 0.62
BMI, kg m2 26.5 (24.4–29.8) 26.5 (24.4–30.0) 26.1 (23.9–29.8) 0.44 26.6 (24.4–30.1) 26.1 (24.4–29.8) 0.72 26.9 (24.4–30.6) 25.2 (24.3–28.9) <0.05
Current smoking, n (%) 35 (21) 29 (24) 6 (14) 0.20 18 (16) 17 (32) 0.02 22 (23) 13 (19) 0.58
Family history of stroke 6 (4) 4 (3) 2 (5) 0.65 3 (3) 3 (6) 0.39 3 (3) 3 (4) 0.69
Comorbidities, n (%)
Arterial hypertension 42 (26) 34 (28) 8 (19) 0.27 26 (23) 16 (30) 0.39 25 (26) 17 (25) 0.91
Hypercholesterolaemia 48 (29) 31 (25) 17 (41) 0.06 31 (28) 17 (32) 0.64 24 (25) 24 (35) 0.14
Diabetes 10 (6) 8 (7) 2 (5) 1.0 6 (5) 4 (7) 0.73 4 (4) 6 (9) 0.32
VTE 7 (4) 3 (2) 4 (10) 0.07 4 (4) 3 (6) 0.68 3 (3) 4 (6) 0.45
Contraceptives or HRT 13 (8) 11 (9) 2 (5) 0.52 11 (10) 2 (4) 0.23 9 (9) 4 (6) 0.43
Pregnancy 9 (6) 8 (7) 1 (2) 0.45 7 (6) 2 (4) 0.72 5 (5) 4 (6) 1.0
Cerebrovascular events
Thrombolysis, n (%) 97 (58) 96 (78) 1 (2)a <0.001 74 (67) 23 (43) 0.01 – – –
Time since the event (months) 8 (6–12) 9 (6–13) 7 (6–10) 0.06 – – – – – –
mRS 0–1 118 (72) 82 (67) 36 (86) 0.006 68 (61) 50 (93) <0.001 36 (37) 50 (74) <0.001
mRS 2–6 47 (28) 41 (33) 6 (14) 0.006 43 (39) 4 (7) <0.001 61 (63) 18 (26) <0.001
Thrombophilia, n (%)
Factor V Leiden 15 (9) 11 (9) 4 (10) 1.0 10 (9) 5 (9) 1.0 6 (6) 9 (13) 0.12
Prothrombin 20210A 3 (2) 1 (1) 2 (5) 0.16 2 (2) 1 (2) 1.0 1 (1) 2 (3) 0.57
PC deﬁciency 5 (3) 5 (4) 0 0.33 4 (4) 1 (2) 1.0 3 (3) 2 (3) 1.0
PS deﬁciency 6 (4) 4 (3) 2 (5) 0.65 5 (5) 1 (2) 0.67 3 (3) 3 (4) 0.69
AT deﬁciency 6 (3) 5 (4) 6 (4) 1.0 3 (3) 3 (6) 0.39 3 (3) 3 (4) 0.70
FVIII > 150% 23 (14) 15 (12) 8 (19) 0.27 17 (15) 6 (11) 0.46 13 (13) 10 (15) 0.81
Homocysteine >15 mM 11 (7) 9 (7) 2 (5) 0.73 8 (7) 3 (6) 1.0 8 (8) 3 (4) 0.53
a2AP Arg407Lys genotypes
Arg/Arg 111 (67) 91 (74) 20 (48) 0.002 – – – 74 (76) 37 (54) 0.003
Arg/Lys 49 (30) 29 (24) 20 (48) 0.003 – – – 21 (22) 28 (41) 0.007
Lys/Lys 5 (3) 3 (2) 2 (4) 0.45 – – – 2 (2) 3 (4) 0.39
Allele frequency – – –
Arg 0.82 0.86 0.71 0.003 – – – 0.87 0.75 <0.005
Lys 0.18 0.14 0.29 0.003 – – – 0.13 0.25 <0.005
a During hospitalization due to transient ischemic attack (TIA) the patient experienced stroke and was treated with thrombolysis.
IS, ischemic stroke; BMI, body mass index; VTE, venous thromboembolism; HRT, hormone-replacement therapy; mRS, the modified Rankin Scale; PC, protein C; PS, protein S; AT, antithrombin; FVIII,
factor VIII; a2AP, alpha-2-antyplasim.
Data are shown as mean  standard deviation (SD) or a median (interquartile range) or number (percentage).
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the whole group was: Arg/Arg: 111 (67%), Arg/Lys: 49 (30%), Lys/
Lys: 5 (3%) and it was in accordance with Hardy–Weinberg
equilibrium (HWE) ( p = 0.88). Allelic frequencies of a2AP
Arg407Lys polymorphism were 0.82/0.18. No differences in
demographic and clinical characteristics between 407Lys allele
carriers and non-carriers were found (Table 1).
No differences in demographic and clinical factors were
observed in thrombolyzed and non-thrombolyzed patients,
with the exception of BMI, which was higher in the former
group ( p < 0.05). Thrombolysis was performed more often in
patients with mRS 2–6 than with mRS 0–1 at the time of acute
event ( p < 0.001). Importantly, the 407Lys allele occurred less
frequently in patients treated with thrombolysis than in non-
thrombolyzed subjects (13% vs. 25%, p < 0.005) (Table 1).
Among thrombolyzed patients, more smokers were found in
the group with mRS 0–1 compared with subjects with mRS 2–6
(32% vs. 6%, p = 0.004; Table 2).
Interestingly, the frequency of Arg407Lys genotypes signif-
icantly differed among controls, IS and TIA patients. Patients
with TIA heterozygous for the 407Lys allele represented a
much larger group compared with those with IS and controls
whose possessed this genotype (48% vs. 24% and 30%; p =
0.015) (Fig. 1A).
In the acute phase of cerebral ischemia mRS score was not
associated with the a2AP Arg407Lys polymorphism or the
known thrombophilia (data not shown). Patients with mRS 0–1
and mRS 2–6 after a few months since the event did not differ
with regard to demographic and clinical factors, including the
known thrombophilia. Only in patients with IS, smoking was
associated with mRS 0–1 ( p = 0.01; Table 2).
In all the patients analyzed together the Arg/Arg genotype
was more frequent in those with mRS 2–6 vs. 0–1 points after a
few months since the event (91% vs. 58%, p < 0.001, respec-
tively; Fig. 1B). Similar observation were obtained for IS
patients (90% vs. 66%, p = 0.004, respectively; Fig. 1B1) and
TIA patients (100% vs. 39%, p = 0.006; respectively, Fig. 1B2)
analyzed separately. Against, the Arg/Lys genotype was found
in the majority of patients with mRS 0–1 vs. 2–6 points
following the event, in total group (38% vs. 9%, p < 0.001,
respectively Fig. 1B), IS patients (31% vs. 10%, p = 0.011) and TIA
patients (56% vs. 0%, p = 0.012). The Lys/Lys genotype occurred
only in a few patients with mRS 0–1 (in 2% of the total, 4% of IS
and 4% of TIA patients) and in no one with mRS 2–6 after 8 (6–
12) months since the event. There were no differences in the
frequency of Lys/Lys genotype between patients with mRS 0–1
and mRS 2–6 ( p = 0.15, p = 0.22, p = 0.59 for the total group, IS
and TIA patients respectively; Fig. 1B, B1 and B2).
The univariate logistic regression model showed that the
excellent outcome (mRS 0–1) assessed after 8 (6–12) months
since the index cerebral ischemia was predicted by the
occurrence of Lys407 allele (OR 7.90; 95% CI, 2.66–23.46,
p < 0.001) but also by the percentage of TIA patients (OR 3.0;
95% CI, 1.17–7.30, p = 0.022) and the lack of treatment with
thrombolysis (OR 2.28; 95% CI, 1.10–4.76, p = 0.028; Table 3). In
multivariate model, after adjustment for sex, age, smoking
status, thrombolyzed treatment and percentage of IS patients,
the excellent outcome (mRS 0–1) was predicted only by the
Arg407Lys polymorphism (OR 6.18, 95% CI, 2.01–18.98,
p = 0.001; Table 3).4. Discussion
This study demonstrates that a common a2AP Arg407Lys
polymorphism may have the impact on prognosis in patients
with ischemic cerebrovascular events of unknown origin. The
patients with Arg/Arg genotype, representing about 67% of the
population, had worse neurological outcomes assessed 8 (6–
12) months since the event compared with those with Arg/Lys
genotype, regardless of the thrombolysis.
Little is known about functional consequences of the a2AP
Arg407Lys polymorphism. Arg407Lys is positioned in the
extended C-terminus of a2AP that binds competitively to the
Lys-binding sites of plasmin [8]. It could be speculated that
substitution of Arg407 with Lys may affect ﬁbrinolysis through
reduction in the efﬁciency of plasmin-a2AP binding. However, it
has been reported that this polymorphism does not inﬂuence
the cleavage of C-terminal of a2AP, plasma clot lysis time, and
ﬁbrin clot structure [9]. It has been demonstrated that the
presence of 407 Lys allele correlates negatively with the
formation of abdominal aortic aneurysm [8] and it does not
differentiate patients with MI vs. control subjects [9]. The
current study suggests the 407Lys allele affects the course of
cerebrovascular ischemia, possibly via mechanisms unrelated
to plasmin-mediated ﬁbrinolysis, for instance matrix metallo-
proteinase expression. This issue requires further investigation.
Importantly, our study shows that carriership of 407Lys
allele may predict less serious sequelae of cryptogenic cerebral
ischemia after a few months while on low-dose aspirin,
though in the acute phase no differences in neurological status
related to this allele were observed. Mechanisms underlying
this observation remained unknown and these differences
cannot be explained by known risk factors for better prognosis
such as the use of thrombolysis or younger age.
In the current study neurological outcomes were better in
smokers as compared to non-smokers receiving thrombolytic
therapy. This phenomenon is in agreement with the previ-
ously described smoking thrombolysis-paradox of an im-
proved outcome. The better outcome (modiﬁed Rankin
Score = 0–2) was found in smokers with IS after intravenous
tPA. Moreover, in smokers after thrombolysis for acute MI low
mortality risk was observed [13,14]. The polymorphism
studied did not confound the impact of smoking on the
outcomes of thrombolysis in stroke patients.
Thrombophilia could possibly play a role as a risk factor for
ischemic cerebrovascular events development. Recently, it has
been shown that inherited deﬁciencies of natural antic-
oagulants such as antithrombin, protein C and protein S are
associated with increased risk of thromboembolic events in
Polish population [15]. Any association between thrombophi-
lia and IS or TIA might introduce the limitations to our
hypothesis. We did not ﬁnd none of these, conﬁrming that
another factors can be more value regarding to the differences
that we observed. Furthermore, our observations were in
agreement with the report about the lack of association
between the presence of inherited thrombophilias and
pathogenic subtypes of ischemic stroke [16]. Also different
report showed that inherited thrombophilia mutations like FV
Leiden or FII phrotrombin G20210A were not a risk factor for
thromboembolic stroke associated with atrial ﬁbrillation [17].
Table 2 – Characteristics of patients with mRS 0–1 and mRS 2–6 during follow-up.
Variables All patients
(n = 165)
mRS 0–1
(n = 118)
mRS 2–6
(n = 47)
p-value IS patients
(n = 123)
mRS 0–1
(n = 82)
mRS 2–6
(n = 41)
p-value Thrombolyzed
patients (n = 97)
mRS 0–1
(n = 63)
mRS 2–6
(n = 34)
p-value
Age, years 45.8  11.4 46  11.6 45.3  11.1 0.70 45.9  11.4 46  12 45.8  11.04 0.92 46.2  10.4 45.7  11.2 47  8.8 0.57
Male, n (%) 57 (35) 39 (33) 18 (38) 0.52 43 (35) 28 (34) 15 (37) 0.79 35 (36) 21 (33) 14 (41) 0.44
BMI, kg m2 26.5
(24.4–29.8)
26. 8
(24.3–30.1)
26
(24.5–29.4)
0.91 26.5
(24.4–30)
27
(24.4–30.2)
26.1
(24.3–28.7)
0.48 26.9
(24.4–30.6)
27.3
(24.3–30.8)
26.5
(25.0–29.0)
0.38
Current smoking, n (%) 35 (21) 29 (25) 6 (13) 0.09 29 (24) 25 (31) 4 (10) 0.01 22 (23) 20 (32) 2 (6) 0.004
Family history of stroke 6 (4) 5 (4) 1 (2) 0.68 4 (4) 3 (4) 1 (3) 1.0 3 (3) 2 (3) 1 (3) 1.0
Comorbidities, n (%)
Arterial hypertension 42 (26) 29 (25) 13 (28) 0.68 34 (28) 22 (27) 12 (29) 0.78 25 (26) 16 (25) 9 (26) 0.91
Hypercholesterolemia 48 (29) 34 (29) 14 (30) 0.90 31 (25) 17 (21) 14 (34) 0.11 24 (25) 13 (21) 11 (32) 0.20
Diabetes 10 (6) 8 (7) 2 (4) 0.73 8 (7) 6 (7) 2 (5) 0.72 4 (4) 2 (3) 2 (6) 0.61
VTE 7 (4) 6 (5) 1 (2) 0.67 3 (2) 2 (2) 1 (2) 1.0 3 (3) 2 (3) 1 (3) 1.0
Contraceptives or HRT 13 (8) 8 (7) 5 (11) 0.52 11 (9) 7 (9) 4 (10) 1.0 9 (9) 5 (8) 4 (12) 0.72
Pregnancy 9 (6) 5 (4) 4 (9) 0.28 8 (7) 4 (5) 4 (10) 0.44 5 (5) 2 (3) 3 (9) 0.34
Cerebrovascular events
Thrombolysis, n (%) 97 (59) 63 (53) 34 (72) 0.03 96 (78) 63 (77) 33 (80) 0.64
Time since the event
(months)
8 (6–12) 8 (6–12) 7 (6–11) 0.50 9 (6–13) 9 (6–13) 7 (6–12) 0.30 9 (6–12.5) 9 (6–13) 8 (6–12) 0.72
Thrombophilia, n (%)
Factor V Leiden 15 (9) 11 (9) 4 (9) 1.0 11 (9) 7 (9) 4 (10) 1.0 6 (6) 4 (6) 2 (6) 1.0
Prothrombin 20210A 3 (2) 3 (3) 0 0.56 1 (1) 1 (1) 0 1.0 1 (1) 1 (2) 0 1.0
PC deﬁciency 5 (3) 3 (3) 2 (4) 0.62 5 (4) 3 (4) 2 (5) 1.0 3 (3) 2 (3) 1 (3) 1.0
PS deﬁciency 6 (4) 3 (3) 3 (6) 0.35 4 (3) 1 (1) 3 (7) 0.11 3 (3) 1 (2) 2 (6) 0.28
AT deﬁciency 6 (4) 5 (4) 1 (2) 0.68 5 (4) 4 (5) 1 (2) 0.66 3 (3) 2 (3) 1 (3) 1.0
FVIII > 150% 23 (14) 17 (14) 6 (13) 0.78 15 (12) 11 (13) 4 (10) 0.56 13 (13) 9 (14) 4 (12) 1.0
Homocysteine>15 mM 11 (7) 7 (6) 4 (9) 0.51 9 (7) 6 (7) 3 (7) 1.0 8 (8) 5 (8) 3 (9) 1.0
Abbreviations see Table 1.
Data are shown as mean  SD or a median (interquartile range) or number (percentage).
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Fig. 1 – The distribution of a2AP Arg407Lys genotypes among patients experienced cryptogenic ischemic stroke (IS) vs.
transient ischemic attack (TIA) and controls (panel A). The Fisher Exact Test was used for statistical analysis. p-value <0.05
was considered statistically significant. For multiple comparisons the Omnibus Fisher Exact Test was used. After Ŝidâc
correction the significance of p-value was considered <0.017. The distribution of a2AP Arg407Lys genotypes among total
patients (panel B), IS patients (panel B1) and TIA patients (panel B2), with the neurological outcomes assessed at 8 (6–12)
months after ischemic stroke (IS) defined by the modified Rankin Scale (mRS) as the excellent recovery (mRS score 0–1) and
poor outcome (mRS score 2–6). Statistical analysis was assessed using Fisher Exact Test. p-value <0.05 was considered
statistically significant.
Table 3 – Regression model of prognostic factors for mRS
0–1.
Variables Univariate regression model
OR 95% CI p-value
407Lys allele 7.90 2.66–23.46 <0.001
Arg407 allele 0.13 0.04–0.38 <0.001
IS 0.33 0.13–0.86 0.022
TIA 3.00 1.17–7.30 0.022
Thrombolysis 0.44 0.21–0.91 0.028
Non-thrombolysis 2.28 1.10–4.76 0.028
Multivariate regression model
407Lys allele 6.18 2.01–18.97 0.0015
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 3 5 2 – 3 5 8 357Our study has several limitations. The number of the
patients studied was relatively low and our ﬁndings require
validation in another larger population. We cannot exclude
that a subset of our patients did have paroxysmal AF as a
causal factor for stroke based on our post stroke diagnostic
work-up, but this factor cannot signiﬁcantly affect our major
ﬁndings. The diagnosis of cryptogenic cerebrovascular events
is always challenging and evolves with rising numbers of their
identiﬁed causes. Finally, in vitro studies are needed to
translate our observations onto a molecular level.5. Conclusions
In conclusion, we have shown that possession of a lysine at
position 407 in a2AP is less common among patients with IS.
Moreover, 407Lys allele is associated with better outcomes
after IS or TIA events. Although our ﬁndings should be replicated
in other studies, the current report provides additional evidence
for the genetically regulated role of a2AP, the inhibitor attracting
rapidly growing attention as a potential new therapeutic agent
[18,19], in cerebral ischemia and its clinical outcomes.
Therefore, not only stroke specialists, internists and general
practitioners [20] but also geneticists need to cooperate for
improving the prognosis and reducing stroke burden worldwide.
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